Cystic Fibrosis Foundation issued the following clinical trial alert in October.
October 6, 2021
Description: This study will look at the safety and effectiveness of VX-121/tezacaftor/deutivacaftor, a drug combination intended to help CFTR protein function closer to normal.
Age: 12 Years and Older
Mutation: One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 19
Length of Participation: 64 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT05033080